Clinical Trial Update: A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerability study of MEDI-570 in systemic lupus erythematosus was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• MEDI-570 (ICOS-targeting monoclonal antibody)

Snippet

Sponsor: MedImmune LLC | Conditions: Lupus Erythematosus, Systemic | Phase 1 | Status: TERMINATED | Results posted: 2014-08-26